Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q1 2024 vs. Q4 2023
How the institutions holding Revelation Biosciences, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 10 | 7 | −3 |
| Shares | 935.0K | 7.65K | −927.3K (−99.2%) |
| Value | $467.3K | $20.9K | −$446.5K (−95.5%) |
New holders (2)
Institutions that held Revelation Biosciences, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Advisor Group Holdings, Inc. | 300 | $822 | 0.00% |
| Royal Bank of Canada | 36 | $0 | 0.00% |
Sold out (5)
Institutions that held Revelation Biosciences, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Walleye Capital LLC | 413,305 | $206.7K |
| Sabby Management, LLC | 403,233 | $201.9K |
| AXA S.A. | 55,971 | $27.5K |
| Geode Capital Management, LLC | 35,709 | $17.9K |
| Citadel Advisors LLC | 24,145 | $12.1K |